Multicystic peritoneal mesothelioma: a systematic review of the literature.

Barbara Noiret,Clarisse Eveno,Florence Renaud,Guillaume Piessen

doi:10.1515/pp-2019-0024

Abstract

Multicystic peritoneal mesothelioma (MCPM) is a particularly rare and benign neoplasm that arises from the peritoneum in reproductive aged females. Its etiopathogenesis is still unclear. The current prevailing theory supports the idea that the tumor is the result of an excessive inflammatory process. Because of a lack of clinical and imaging presentation, the diagnosis is intricate, and heavily relies on case reports and short studies. A histological analysis with immunohistochemistry is required for a definitive diagnosis. To date, there is no standard treatment recommended for MCPM. However, some studies suggest proceeding with a cytoreductive surgery and a hyperthermic intraperitoneal chemotherapy combining CISPLATIN and DOXORUBICIN, due to a high incidence of recurrence rate after medical treatment or surgery alone and potential malignant transformation.

Highlights

Peritoneal mesothelioma is a rare disease characterized by peritoneal malignancy occurring in the mesothelium of the pleural, peritoneal and pericardial cavities, and tunica vaginalis covering the testes
Multicystic peritoneal mesothelioma (MCPM) is a rare and benign neoplasm that arises from the peritoneum in reproductive aged females
Several therapeutic approaches for MCPM have been reported from simple observations to complete surgical resections, but the commonly accepted strategy combines cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC)

Summary

Introduction

Peritoneal mesothelioma is a rare disease characterized by peritoneal malignancy occurring in the mesothelium (lining cells) of the pleural, peritoneal and pericardial cavities, and tunica vaginalis covering the testes. Abstract: Multicystic peritoneal mesothelioma (MCPM) is a rare and benign neoplasm that arises from the peritoneum in reproductive aged females. Some studies suggest proceeding with a cytoreductive surgery and a hyperthermic intraperitoneal chemotherapy combining CISPLATIN and DOXORUBICIN, due to a high incidence of recurrence rate after medical treatment or surgery alone and potential malignant transformation.

Results

Conclusion